Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
Mathew B, Amaechi C, Asante K, Albuquerque E, Benedict A, Kneeream E, Lopez L, et al
You need to record the date, time, dose amount, injection site, and any side effects for each injection
The Diabetes Prevention Program and Look AHEAD trials demonstrated that intensive lifestyle interventions produce clinically meaningful metabolic improvements, and these effects are additive with pharmacotherapy
Key Points: GI symptoms are the most common adverse effects, ranging from expected nausea and vomiting to gastroparesis and, rarely, functional obstruction Delayed gastric emptying has important airway implications and a cautious approach to airway management is warranted Biliary disease is one of the most clinically significant complications, particularly early in treatment and with rapid weight loss Pancreatitis is rare, and current evidence does not support a strong causal relationship EDKA and AKI are uncommon but important to recognize in the right context Conclusions: GLP-1 receptor agonists have transformed the management of diabetes and obesity, with clear benefits in weight loss, glycemic control, and cardiovascular outcomes
US$ 21.67
US$ 21.77
US$ 26.31
US$ 29.37
US$ 25.13
US$ 25.47
US$ 28.29
US$ 23.31
US$ 26.17
US$ 20.67
